- Psychiatric Times Vol 20 No 10
- Volume 20
- Issue 10
Risperidone May Lower Risk of Falls
A study presented at the Eleventh International Congress of the International Psychogeriatric Association showed that risperidone 1 mg/day reduced the risk of falls in ambulatory patients with dementia. Data from 537 patients in a randomized, double-blind, placebo-controlled, 12-week, multicenter study of three doses of risperidone were included.
A study presented at the Eleventh International Congress of the International Psychogeriatric Association showed that risperidone (Risperdal) 1 mg/day reduced the risk of falls in ambulatory patients with dementia. Data from 537 patients in a randomized, double-blind, placebo-controlled, 12-week, multicenter study of three doses of risperidone (0.5 mg, 1 mg and 2 mg) were included.
During the trial, 109 patients (20.3%) fell. There was a statistically significantly lower fall rate for the patients taking 1 mg of risperidone than for patients taking placebo (12.7% versus 22.3%, p=0.04).
Behavioral symptoms were assessed with the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) scale; only wandering was associated with an increased rate of falls. Eighty-three (21.1%) of the 393 patients with a baseline wandering score of >0 fell--EAD
Articles in this issue
over 22 years ago
Research Fails to Link Talk Therapy With Heart Attack Survivalover 22 years ago
Genetic Components of Depression Identifiedover 22 years ago
Expressions of Social Anxiety in Asian-Americansover 22 years ago
Cultural Psychiatric Services: Past, Present and Futureover 22 years ago
Trauma and Violence in Childhood: A U.S. Perspectiveover 22 years ago
Hispanics and Psychiatric Medications: An Overviewover 22 years ago
Are Assessment and Treatment Influenced by Ethnicity and Gender?over 22 years ago
Cognitive Therapy's Faulty SchemaNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
